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Abstract 
Current preclinical drug testing does not predict some forms of adverse drug reactions in humans.   
Efforts at improving predictability of drug-induced tissue injury in humans include using stem cell 
technology to generate human cells for screening for adverse effects of drugs in humans.  The 
advent of induced pluripotent stem cells means that it may ultimately be possible to develop 
personalised toxicology to determine inter-individual susceptibility to adverse drug reactions.  
However, the complexity of idiosyncratic drug-induced liver injury (DILI) means that no current 
single cell model, whether of primary liver tissue origin, from liver cell lines, or derived from stem 
cells, adequately emulates what is believed to occur during human DILI.  Nevertheless, a single cell 
model of a human hepatocyte which emulates key features of a hepatocyte is likely to be valuable in 
assessing potential chemical risk; furthermore understanding how to generate a relevant hepatocyte 
will also be critical to efforts to build complex multicellular models of the liver. Currently, 
hepatocyte-like cells differentiated from stem cells still fall short of recapitulating the full mature 
hepatocellular phenotype.  Therefore, we convened a number of experts from the areas of 
preclinical and clinical hepatotoxicity and safety assessment, from industry, academia and regulatory 
bodies, to specifically explore the application of stem cells in hepatotoxicity safety assessment, and 
to make recommendations for the way forward.  In this short review, we particularly discuss the 
importance of benchmarking stem cell-derived hepatocyte-like cells to their terminally-
differentiated human counterparts using defined phenotyping, to make sure the cells are relevant 
and comparable between labs, and outline why this process is essential before the cells are 
introduced into chemical safety assessment. 
 
Prediction of adverse drug reactions in the liver: why it is important, limitations of current 
in vitro models and how stem cells may prove useful in drug screening 
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Adverse drug reactions (ADRs) are a significant clinical problem, resulting in considerable patient 
morbidity and mortality
(1)
 and thus represent a major financial burden on healthcare systems.  ADRs 
also represent a major challenge for the pharmaceutical industry leading to attrition of drugs in 
development and the withdrawal of drugs post-licensing
(2)
.  Amongst different forms of ADRs, the 
liver is particularly susceptible to drug toxicity; drug-induced liver injury (DILI) is the second highest 
cause of attrition and accounts for more than 50% of cases of acute liver failure
(3)
.   
The principal cause of these high attrition rates is the failure of current preclinical drug testing 
procedures to effectively predict idiosyncratic DILI in patients
(2)
.  This is true for in vitro models  and 
even for in vivo models - a recent study that related the  preclinical assessment of drugs with the 
occurrence of DILI in the clinic showed that between 38% (Medline database: 269 out of 710 
compounds) and 51% (EMEA database: 70 out of 137 compounds) of drugs that subsequently 
caused liver injury in patients were not predicted from animal studies
(4)
. Concerted worldwide 
efforts are therefore required to improve the assessment of hepatotoxic risk for new compounds.  In 
Europe, the SEURAT (http://www.seurat-1.eu/pages/cluster-projects/scrtox.php) and MIP-DILI 
(http://www.mip-dili.eu/) consortia, and in the US, DILIN (http://www.dilin.org/) and iSAEC 
(http://www.saeconsortium.org/) are attempting to address this issue.  The clinical manifestation of 
DILI indicates that it is a multi-dimensional and multi-faceted disease
(5)
. Indeed, the diagnosis of DILI 
is largely based upon exclusion criteria
(5)
.  Although the use of currently available cell lines and 
primary human hepatocyte models has been able to correctly classify a number of DILI compounds 
as hepatoxins
(6-9)
, idiosyncratic DILI is inherently difficult to model in the laboratory, and therefore 
highly unlikely to be predicted by simplistic screening strategies, often based on single-cell models 
involving cell lines.  Many approaches use liver-derived cancer cell lines, e.g. HepG2 and HepaRG, 
which may have value for identifying drugs lacking a propensity to cause idiosyncratic DILI (90-95% 
predictability), but perform less well for positive predictions (50-89%)
(9-11)
.  Metabolically-competent 
freshly-isolated, or cryopreserved human primary adult hepatocytes are still considered to be the 
gold-standard single cell model of DILI. Nevertheless, human hepatocytes are difficult to source, they 
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are also costly and functionally variable (reflecting variation in the human population), they undergo 
severe stress during the isolation process and, critically, they rapidly lose key functions when 
cultured in vitro.  Moreover, it is important to note that hepatocyte toxicity per se is not the sole 
cause of hepatotoxicity which, in the intact liver, may involve multiple different cell types including 
lymphocytes and macrophages.  Yet it is reasonable to assume from the work of several groups, over 
many years, that a metabolically-competent hepatocyte will be an essential component of any 
model of hepatotoxicity in vitro.  Thus, a robust and reproducible metabolically-competent 
hepatocyte-like cell derived from directly reprogrammed cells, or from pluripotent stem cells, would 
represent a major step forward for the development of a new generation of in vitro models.  
The imperatives of industry and academia are driven by different model requirements. The priority 
for industry is a cost-effective and scalable high-throughput screening model that has direct input 
into ‘go/no go’ decision making during drug development, whilst academic scientists are driven by 
the need to understand hepatic physiology and the mechanistic basis of DILI. Hepatocytes derived 
from stem cells can, however, be central to both of these objectives.  Whilst significant progress 
towards a functional hepatic phenotype has been made, it is clear that stem-cell-derived 
hepatocyte-like cells (SC-HLCs) still fall well short of recapitulating the full mature hepatocellular 
phenotype
(12-15)
.   
Because of the importance and likely impact of developments in this field, scientists with expertise in 
preclinical and clinical hepatotoxicityand complex and novel forms of in vitro cell culture, 
representing industry, academia and regulatory bodies, assembled at a workshop at the University 
of Liverpool, under the auspices of the European Partnership for Alternative Approaches to Animal 
Testing (EPAA) (http://ec.europa.eu/growth/sectors/chemicals/epaa/index_en.htm) and the MRC 
Centre for Drug Safety Science (https://www.liverpool.ac.uk/drug-safety/).  The purpose of the 
workshop was to specifically explore the application of stem cells in hepatotoxicity safety 
assessment, and to make recommendations for the way forward.  This workshop follows the 
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EPAA/NC3Rs (National Centre for the Replacement, Refinement and Reduction of Animals in 
Research) (https://www.nc3rs.org.uk/) “Stem Cells in Safety Testing Forum” workshop that took 
place in 2013, with a mandate to provide a platform for permanent dialogue between research 
groups, to share experiences, problems, successes and opportunities. 
Current challenges in the use of stem cell-derived hepatocytes in the safety assessment of 
new chemical entities   
It is clear from a large number of studies
(13, 14, 16-47)
 (see Table 1) that hepatocytes generated from 
stem cells are not currently sufficiently mature to emulate an adult primary human hepatocyte, and 
that these cells are probably closer in phenotype to a fetal hepatocyte
(12)
.   Many studies using SC-
HLCs purport to demonstrate a hepatocyte-like phenotype but do not actually incorporate a 
physiologically-relevant benchmark (e.g. freshly-isolated human hepatocytes) and a non-
physiologically-relevant benchmark (e.g. HepG2 cells);  in addition, often very few markers of the 
hepatic phenotype are used and  studies do not always employ quantitatively-relevant assays (e.g 
mass spectrometry).  Thus, inadequate benchmarking has hampered the field and there is likely 
significant value in identifying a common framework that might allow end users to readily interpret 
cell phenotype.   
Despite the challenges in generating mature hepatocytes, SC-HLCs have recently been shown to 
retain the cytochrome P450 (CYP) expression profile (specifically CYP2C9 and CYP2D6) of the donor 
hepatocyte
(48, 49)
, yielding metabolism-specific toxicity for CYP2C9 (benzbromarone) and CYP2D6 
(tamoxifen).  This is highly relevant as the CYPs are key enzymes of Phase I drug metabolism, that 
play a key role in the chemical functionalization and eventual elimination of drugs from the body, 
but which also can yield significant intracellular concentrations of chemically reactive metabolites, 
leading to cellular and tissue damage of the liver, and therefore DILI (for a  review of this area, see 
Park et al, 2011
(50)
). 
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The recent studies outlined above 
(48, 49)
 are particularly important as they suggest that modelling 
some forms of DILI (such as that elicited by benzbromarone or tamoxifen) using stem cell-derived 
hepatocytes may be possible, and that ultimately the challenges to generating a fully mature HLC 
will not always be insurmountable.  
We consider that there are at least three major challenges to producing mature, physiologically- and 
pharmacologically-relevant hepatocytes from stem cells: 
• Stem cell-derived hepatocytes must mimic several years of development in vivo. 
• Like primary hepatocytes, the stem cell-derived hepatocyte phenotype is unstable currently 
in culture
(51)
. 
• At the moment, it is difficult to emulate the complexity of the liver, with its unique blood 
supply and exposure to  relevant concentrations of intestinal products and nutrients in vitro. 
Development of three-dimensional culture systems that employ co-cultivation of all cell 
types found in the liver acinus is likely to be required if we are to recapitulate the liver in 
vitro
(51, 52)
. Following on from this, it is important to remember that a hepatocyte is not a 
single entity but varies functionally according to the hepatic zone in which it is located.  The 
consequence of this is that some hepatotoxins induce hepatocellular damage in a zone-
specific manner and this has not yet begun to be addressed meaningfully in the stem cell 
field, as we focus our attempts on improving basic functional maturity of the SC-derived 
cells, but it will need to be considered. 
Despite these challenges, there are many promising leads in development, e.g. the discovery of 
several small molecule inducers of the hepatic phenotype
(53)
, and the finding that microbial-derived 
secondary metabolites to which immature hepatocytes are likely to be exposed to post-partum may 
induce a significant increase in maturity.  A further paradigm comes from the exploitation of SC-HLCs 
for demonstration of efficacy; specifically, for the reversal of the hepatic alpha1-antitrypsin-deficient 
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phenotype, shown by Yusa et al
(54)
.  This study demonstrated restoration of alpha1-antitrypsin 
activity was possible on a “sufficiently” mature background, rather than one that was necessarily 
fully mature and identical to a freshly-isolated adult hepatocyte. Furthermore, a recent study by 
Ware et al
(55)
 suggests that DILI detection is possible using SC-HLCs in micopatterned co-cultures, in 
which cells mature to significant levels. It is worth remembering that the hepatocyte exhibits more 
individual functions (>500) than any of the other ~200 terminally differentiated cell types in the 
human body.  Therefore it is perhaps not surprising that this cell is amongst the most challenging to 
mature, and we should still continue to explore the utility of hepatocyte-like cells as prototypes 
rather than await the final “product”. 
Lessons learned from the use of stem cell-derived cardiomyocytes in detecting 
cardiotoxicity 
A parallel example, from which lessons can be learned, comes from the use of stem cells in the 
assessment of drug-induced cardiotoxicity – a primary cause of drug attrition. Cardiotoxicity, 
specifically QT prolongation, has already been successfully modelled using such cells
(56-58)
. In 
comparison, there is only very recent evidence that SC-HLCs are able to recapitulate hepatotoxic 
events
(49, 55)
.   The difference between successful application of cardiac models compared with 
hepatic models may reflect the relative specificity of some forms of drug-induced cardiotoxicity, in 
contrast with the rather pleiotropic and diverse manifestations of hepatotoxicity, at the molecular, 
cellular, and tissular level
(59)
.  Cardiotoxicity often arises due to drug-induced electrical perturbation 
of the cell interfering with its contractile function
(60)
. Here, the stem cell-cardiomyocyte model 
provides advantages over recombinant tumour models. Thus, the impact of drugs that cause simple 
single ion channel or complex multi-channel perturbation can be related to cardiomyocyte 
arrhythmias and abnormalities in contractility
(61)
. In hepatotoxicity, however, there are myriad 
factors required to recapitulate toxicity, especially idiosyncratic toxicity where the immune system is 
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also implicated. This is compounded by inter-individual variation in expression of xenobiotic 
metabolism and transporter proteins in addition to the chemistry of each drug. 
Whilst protocols to differentiate stem cells towards cardiomyocytes generate cells that are not fully 
mature
(61)
, these cells can recapitulate some facets of the cell phenotype required to produce 
specific forms of cardiotoxicity. This has prompted major international efforts to search for methods 
to further mature stem cell cardiomyocytes. Each incremental improvement made towards 
progressing the compliment of ion channels, regulatory pathways and structural proteins to the 
complete sets found in adult cells will dramatically increase the utility of stem cell cardiomyocytes. 
The demonstration that specific toxicological phenotypes can be mimicked by stem cell-derived 
cardiomyocytes allows the cell model to be considered “fit-for-purpose”. This raises the notion of 
using stem cell-derived hepatocytes that may be sufficiently mature for a specific toxicological 
assessment even though the cells may lack the full hepatic functionality with respect to drug 
metabolism, transporter expression etc. For example, where one or two cytochrome P450s (P450s), 
some relevant phase II enzymes, such as the glutathione transferases and UDP-glucuronyl 
transferases, and some Phase III proteins (influx and efflux transporters) are expressed at a set and 
reproducible % of a “typical” human hepatocyte, this cell may in some cases represent a significant 
and useful model in understanding specifically drug metabolism and possible metabolism-dependent 
toxicity.  
 
The Importance of Phenotypic Characterisation  
For the field to continue to move forward and develop liver cell models that are useful in prediction 
and mechanistic understanding of DILI, it is essential that the SC-HLCs are properly benchmarked 
against currently used and relevant human cells, especially fresh primary human hepatocytes and 
HepG2 cells (see Table 1 and Figure 1).  Moreover, the phenotype of the HLCs must be as 
reproducible as possible, and they should be fully characterised, particularly with reference to the 
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pharmacological phenotype (using a defined panel of training compounds).  It is also important that 
the cell model can provide a static point of reference that can be used to ascertain if real progress is 
being made. When assessing novel models of hepatotoxicity it is important to use functional assays 
employing quantitative mass spectrometry whenever possible, as this is now being routinely 
employed 
(48, 62, 63)
in order to determine the true phenotype of the model.  A global proteomic 
analysis however may be the most appropriate way to characterise the cells, as this would represent 
a broad visualisation of the physiological phenotype of the cells.  Similarity to freshly-isolated 
hepatocytes/tissue can be established through proteomics and targeted multiple- reaction-
monitoring (MRM)-based mass spectrometric analysis of key proteins, such as CYP450s, transporters 
and intracellular signalling molecules and metabolic and cellular uptake profiles determined. 
Developments in mass spectrometric technologies mean that it is now possible to analyse small 
panels of proteins (for example 10-20 transporters or P450s) using MRM, in order to quantify 
proteins per cell at an absolute level
(64)
.  This would ensure valid comparisons between currently 
used models and cells, as well as cells that are developed in the future. Given the inherent 
deficiencies in a transcriptomic-only approach, which are well-illustrated in a recent landmark paper 
reporting only a 39% correlation between mRNA and protein at a global level
(65)
, measuring mRNA 
levels is not recommended for cell characterisation purposes. 
As part of a comprehensive assessment of HLC phenotype, recent developments in the field of 
hepatocyte-selective translatable biomarkers (e.g. miR122
(66)
) might allow us to translate the 
response to chemicals between humans, model organisms and cells including SC-HLCs and it is likely 
that additional novel and selective biomarkers will be identified in the future using models such as 
SC-HLCs. This is an important area for industry which requires selective and translatable biomarkers 
of liver injury to monitor potentially hepatotoxic compounds in the clinic. 
The recently developed concepts of adverse outcome pathways and points of departure
(67) 
in the 
field of systems toxicology should also be considered in the context of phenotyping the response to 
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chemical exposure of hepatocyte-like cells that express relevant proteins and pathways.  To this end, 
cells expressing genetic reporters for key adaptive pathways such as Nrf2, PXR andNF-κB will be 
useful as a means for understanding the earliest events in the biological response to a drug
(68-70)
.  
However, it is imperative that we develop ways to bridge our findings from these molecular 
investigations to what actually occurs in DILI in humans –the development of novel bridging 
biomarkers that allow extrapolation from in vitro test system to man will be invaluable in this 
endeavour. Another important development in relation to hepatocyte genotype and phenotype in 
DILI is the derivation of SC-HLCs with specific polymorphisms relevant to drug toxicology. Of 
particula  interest in this regard is the developing use of CRISPR technology in SC-HLCs to edit, for 
example, genes relevant to drug metabolism and toxicity thereby providing a wild type cell and an 
almost identical cell with an alteration in drug metabolism and toxicological responses, respectively. 
Finally, phenotypic characterisation may be assisted by a better understanding of the mechanisms 
contributing to de-differentiation or loss of phenotype.  Consideration of the cellular complexity of 
the liver and the functional sophistication of a hepatocyte makes it unsurprising that the 
maintenance of a fully functional hepatocyte in culture is difficult to achieve
(71)
. The cells have been 
removed from their neighbouring hepatocytes, disrupting their gap junctions and tight junctions 
which are important for their phenotype, as well as their juxtaposed non-parenchymal cells, which 
may also be responsible for the differentiated hepatocyte phenotype
(72, 73)
.  Dedifferentiation is not a 
unique process to the liver; when cardiomyocytes are cultured, they also lose some of their in vivo 
phenotype, e.g. the t-tubules are lost, glycogen is accumulated and chromatin becomes dispersed in 
vitro
(74)
.  However, the key difference between hepatocytes and myocytes is the importance of the 
metabolic phenotype with respect to drug toxicity, and it is this function – particularly the phase I 
CYP450 capacity – that is most rapidly and profoundly depleted
(71, 75)
  - and it is also this function, at 
a defined proportion of the activity present in human liver, that is essential in any in vitro model of a 
hepatocyte    
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One area of research that could have a significant impact on attempts to re-establish a functional 
hepatocyte from stem cells, is the investigation of the precise cellular mechanisms underlying the 
de-differentiation process that occurs in hepatocytes once they have been removed from the liver. 
Whilst the factors driving de-differentiation may not be identical to those that drive differentiation, 
it is likely that one or more pathways and processes uncovered through research into de-
differentiation will be amenable for testing in differentiation experiments.  If it is not understood 
how to maintain the dynamic and sophisticated machinery of a fully mature hepatocyte in vitro, it is 
likely to be difficult to capture the same phenotype in a stem cell-derived cell grown under similar 
conditions. 
 
Summary and recommendations  
• DILI is a complex, multi-dimensional disease, with variable phenotype between individuals, 
even for a single drug. There is essentially no ideal in vitro or in vivo model that recapitulates 
all of the potential features of this injury.  
• The aspiration of the field is a “perfect” mature hepatocyte as it exists in a liver - this has not 
yet been achieved.  Until it is, hepatocyte-like cells with known, quantifiable and  
reproducible proportions of the function of two widely-used standards, i.e. primary fresh 
human hepatocytes, and HepG2, will be valuable biological models to explore the 
physiological, pharmacological and toxicological response of hepatocytes to drug exposure. 
• These “immature” cells should be explored as models of chemical perturbation using genetic 
reporters and biomarkers, with continual effort to relate findings to human DILI. 
• Global proteomic analysis aligned with biological pathway analysis may be the most 
appropriate way to characterise HLCs – a small targeted panel of proteins will also help to 
compare cells for key proteins and functions using absolute quantitation by mass 
spectrometry.  Crucially, this will advance the field by avoiding over-reliance on a small panel 
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of liver proteins, such as albumin, that may not be representative of a fully mature and 
functioning liver cell. 
• It is likely that niche creation in vitro, deploying enhanced matrices
(13)
  and even 3D 
bioprinting
(76)
 , and incorporating other cell types such as endothelial cells
(76, 77)
  and Kupffer 
cells
(78)
  inter alia, will mature and support hepatocyte function. 
• A small panel of chemical benchmarks will be needed to probe the physiological, 
pharmacological and toxicological function of the cells, only once they have been properly 
phenotyped.  There is little point in exposing HLCs to chemicals chosen as hepatotoxins in 
man unless we fully characterise the cells. 
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Table 1. Summary of studies post-2007 of HLC-derivation from human pluripotent stem cells (adapted from Table 1 and Table 2, Kia et al
(13)
 with 
modification). Note the limited number of Phase 1 and 2 phenotyping markers generally employed in the characterization of the HLCs. 
Reference Method of stem cell differentiation  Differentiation efficiency 
% ALB +ve HLCs 
PHENOTYPING: Phase I and II enzyme activity 
Stem cell (cell line) Culture format Differentiation factors % ALB +ve HLCs  
(assay method) 
Enzyme (assay method) % hPH 
comparator 
Other comparators 
Cai et al., 2007
(14)
 hESC (H1, H9) Monolayer, EB 
formation 
AF V, AA, ITS, BMP2, FGF4, HGF, OSM, DEX 70 (ICC) CYP2B6 (Fluorescence) ND hESC  
Ek et al., 2007
(15)
 hESC (SA002, SA002.5, SA167) Monolayer Proprietary differentiation medium, FGF2  ND CYP1A1 (Fluorescence) 
CYP3A4 (Fluorescence) 
0 
0 
 ─ 
 ─ 
Söderdahl et al., 
2007
(16)
 
hESC (SA001, SA002, SA002.5, 
AS034, SA121, and SA167) 
Monolayer Proprietary differentiation medium, bFGF ND GST (Fluorescence) 80 HepG2  
Hay et al., 2008
(17)
; 
Godoy et al., 2015
(11)
; 
Cameron et al., 2015
(10)
 
hESC (H1, H9) Monolayer AA, Wnt3a 90 (ICC) CYP 1A2 (LC-MS-MS) 
CYP1A2 (Luminescence) 100             
CYP3A4 (Luminescence) 100 
24 hESC  
Shiraki et al., 2008
(18)
 hESC (Khes-1) Co-culture with 
M15 cell line 
AA, BMP4, bFGF, HGF, DMSO, DEX, Ly294002 9 (ICC) ND ─ ─ 
Agarwal et al.,2008
(19)
 hESC (WA01, WA09) Monolayer AA, FGF4, HGF, BSA, OSM, DEX 67.4 (ICC) ND ─ ─ 
Moore et al., 2009
(20)
 hESC (H1) Monolayer, EB 
formation 
AA, Wnt3a, HGF, OSM, DEX 72.8 (ICC) CYP 1A2 (Fluorescence) ND hESC-derived HLCs in culture 
 media of different components 
Basma et al., 2009
(21)
 hESC (H1) Monolayer, EB 
formation 
AA, FGF2, HGF, DMSO, DEX 55.5 (ICC) CYP1A (Fluorescence) 
CYP3A (LC-MS-MS) 
30 
90 
─ 
─ 
Song et al., 2009
(22)
 hESC (H1),  
hiPSC (hFb-derived 3U1, 3U2) 
Monolayer AF V, AA, ITS, BMP2, FGF4, OSM, 
DEX, KGF, B27 
60 (ICC) CYP2B6 (Fluorescence) ND hiPSC-derived versus hESC-
derived HLCs 
Duan et al., 2010
(23)
 hESC (H9) Monolayer AA, sodium butyrate, BMP2, 
BMP4, FGF4, HGF DMSO, B27 
75-90 (ICC, FACS) CYP1A2 (LC-MS-MS) 
CYP2C9 (LC-MS-MS) 
CYP2D6 (LC-MS-MS) 
CYP3A4 (LC-MS-MS) 
100 
60 
95 
90 
─ 
─ 
─ 
─ 
Synnergren et al., 
2010
(24)
 
hESC (SA002, SA167, SA461) Monolayer AA, ITS, FGF1, FGF2, BMP2, 
BMP4, HGF, OSM, DEX 
ND ND ─ ─ 
Touboul et al., 2010
(25)
 hESC (H9) Monolayer AA, BMP4,FGF2, FGF4, FGF10, 
HGF, EGF, retinoic acid, 
SB431542, Ly294002 
ND CYP3A (Bioluminescence) ND ─ 
Brolén et al., 2010
(26)
 hESC (SA001, SA002, SA002.5, 
SA167) 
Monolayer AA, BMP2, BMP4, FGF1, FGF2, 
HGF, OSM, DEX, Wnt3A 
ND CYP1A (LC-MS-MS) 
CYP2C (LC-MS-MS) 
CYP2A (LC-MS-MS) 
ND Spontaneously differentiated 
hESC-derived HLCs, HepG2 
Ghodsizadeh et al., 
2010
(27)
 
hiPSC (hFb-derived) EB formation AA, FGF2, HGF, DMSO, DEX 50 (FACS) CYP2B6 (Fluorescence) ND hiPSC 
Liu et al., 2010
(28)
 hESC (WA01, WA09),  
hiPSC (hPH-derived) 
Monolayer AA, FGF4, HGF, OSM, DEX ND CYP1A2 (Bioluminescence) 
CYP3A4 (Bioluminescence) 
ND ─ 
Si-Tayeb et al., 2010
(29)
 hESC (H9), hiPSC (hFb-
derived)  
Monolayer AA, BMP4, FGF2, OSM, B27 80 (FACS) ND ─ ─ 
Sullivan et al., 2010
(30)
 hiPSC (hFb-derived) Monolayer AA, HGF, Wnt3A, DMSO, OSM, 
hydrocortisone, tryptose 
phosphate broth, B27 
70-90 (ICC) CYP1A2 (Bioluminescence) 
CYP3A4 (Bioluminescence) 
ND ─ 
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Rashid et al., 2010
(31)
 hiPSC (hFb-derived) Monolayer AA, BMP4, FGF2, HGF, OSM, 
Ly294002, CHIR99021 (GSK-3 inhibitor) 
83 (FACS) CYP3A4 (Bioluminescence) ND hiPSC 
Zhang et al., 2011
(32)
 hESC (H9), hiPSC (hFb-
derived) 
Monolayer, EB 
formation 
AA, BMP2, FGF4, HGF, KGF, 
OSM, DEX 
60-80 (ICC, FACS) CYP3A4 (Bioluminescence) 0.32 hESC-derived HLCs 
Bone et al., 2011
(33)
 hESC (Shef1, Shef3) Monolayer FGF4, HGF, OSM, DEX, 1 m 
(GSK-3 inhibitor) 
ND ND ─ ─ 
Yildirimman et al., 
2011
(34)
 
hESC (SA002) Monolayer Proprietary differentiation 
medium 
ND CYP1A2 (LC-MS-MS) 
CYP3A4 (LC-MS-MS) 
CYP2B6 (LC-MS-MS) 
CYP2C9 (LC-MS-MS) 
CYP2C19 (LC-MS-MS) 
50 
50 
10 
50 
50 
─ 
─ 
─ 
─ 
─ 
Chen et al., 2012
(35)
 hESC (H9), hiPSC (hFb-
derived, CFB46) 
Monolayer AA, ITS, HGF, Wnt3A, OSM, 
DMSO, DEX 
ND CYP3A4 (Bioluminescence) 100 hiPSC 
Cayo et al., 2012
(36)
 hiPSC (FH patient JD 
fibroblast-derived) 
Monolayer OCT4, SOX2, NANOG, LIN28 ND ND ─ ─ 
Schwartz et al., 2012
(37)
 hiPSC (hFb-derived) Monolayer AA, BMP4, FGF2, HGF, OSM 80 (ICC) ND ─ ─ 
Takayama et al., 
2012
(38)
 
hES (H9), hiPSC (hFb-derived, 
MCR5 & 201B7) 
Monolayer AA, SOX17, HEX, BMP4, FGF4, 
 LacZ, HNF4α, HGF, OSM,  DEX 
ND CYP3A4 (Fluorescence) 
CYP2C9 (Fluorescence) 
CYP1A2 (Fluorescence) 
100 
> 10 
< 1 
─ 
─ 
─ 
Choi et al., 2013
(39)
 hiPSC (derived from AAT 
deficient patients) 
Monolayer B27, AA, FGF4, HGF, OSM, DEX ND CYP3A4 (Bioluminescence) 
CYP2D6 (Bioluminescence) 
CYP2C19 (Bioluminescence) 
CYP1A2 (Bioluminescence) 
80 
70 
90 
90 
─ 
─ 
─ 
─ 
Ramasamy et al., 
2013
(40)
 
hESC (H1) Monolayer & 3D 
culture in 
Algimatrix plate 
AA, DMSO, HGF, OSM ND CYP3A4 (Bioluminescence) ND HepG2 
Gieseck et al., 2014
(41)
 hiPSC (hFb-derived) Monolayer, 3D-
single cell or 
Clump culture 
 in RAFT system  
AA, FGF2,BMP4, LY-294002, Hepatozyme-SFM  ND CYP3A4 for 2D Day 35 
(HPLC-MS) 
CYP3A4 for 3D Day 45 
(Bioluminescence) 
4 
25 
─ 
Jia et al., 2014
(42)
 hiPSC (from urine cells of HA 
patient) 
Monolayer, EB 
formation 
AA, FGF4, BMP2, HGF, KGF, OSM, DEX 64 (FACS) ND ─ ─ 
Avior et al., 2015
(43)
 hESC  (I3) Monolayer AA, B27, Wnt3A, HGF, DMSO, DEX, OSM, FGF2, 
LCA, MK4 
83 (FACS) CYP3A4, 1A2 (Fluorescence) 
CYP2E1, 2C9 (Fluorescence) 
30 
8 
HepG2, hESC without LCA/MK4 
Chien et al., 2015
(44)
 hiPSC (from dental pulp 
stromal cells) 
Co-culture with 
MEF, EB 
formation 
AF V, AA, FGF4, BMP2, HGF, KFG, OSM,  
DEX, B27, miR122 (delivered by PU-PEI in CHC) 
ND ND ─ ─ 
 
Abbreviations: AA, activin A; AF V, albumin fraction V; bFGF, human recombinant basic FGF; BMP, bone morphogenic protein; BSA, bovine serum albumin; 
CHC, carboxymethyl-hexanoyl chitosan; DEX, dexamethasone; DMSO, dimethyl sulfoxide; EGF, epidermal growth factor; FACS, fluorescence-activated cell 
sorting; FGF, fibroblast growth factor; GFP, green fluorescent protein; GSK, glycogen synthase kinase; Hepatozyme-SMF, hepatozyme serum free medium; 
HEX, hematopoietically-expressed homeobox protein; hESC, human embryonic stem cell; hiPSC, human induced pluripotent stem cell; HLCs, hepatocyte-like 
cells; HGF, hepatocyte growth factor; HNF4alpha, hepatocyte nuclear factor 4 alpha; ICC, immunocytochemistry; ITS, insulin-transferrin-selenium; KGF, 
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keratinocyte growth factor; LacZ, beta-D-glactosidase; Ly294002, phosphoinositide 3-kinase inhibitor; miR122, microRNA 122; ND, not determined; OCT, 
octamer-binding transcription factor; OSM, oncostatin M; PU-PEI, biodegradable polyurethane-graft-short-branch polyethylenimine; qRT-PCR, quantitative 
real time polymerase chain reaction; SB431542, inhibitor for activin receptor-like kinase receptors ALK5, ALK4 and ALK7; SOX, sex determining region Y-box;  
Wnt3a, wingless-type MMTV integration site family, member 3a   
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